7.6 Hydration and Electrolytes GLP-1 therapy may reduce thirst perception in some individuals
In pharmaceutical MDL cases, courts may also impose additional case-specific requirements

Weeks 0-2 (Acute withdrawal phase): Dietary approach: Low-fat, low-fiber, small frequent meals (6 meals per day, 200-300 calories each) Avoid: Large meals, high-fat foods, high-fiber foods (raw vegetables, whole grains, legumes) Liquid nutrition: Supplement with protein shakes or meal replacement drinks if solid food tolerance is poor Prokinetic consideration: Metoclopramide 5-10 mg before meals can be started if nausea is severe (requires prescription and monitoring for side effects) Antiemetic support: Ondansetron 4-8 mg as needed for breakthrough nausea Weeks 2-6 (Early recovery phase): Dietary progression: Gradually increase meal size and reintroduce soft solids (scrambled eggs, mashed potatoes, cooked vegetables) Continue avoiding: High-fat and high-fiber foods Prokinetic taper: If metoclopramide was started, attempt to reduce dose or frequency after week 4 Ginger and peppermint: Natural prokinetics that support gastric emptying without prescription Weeks 6-16 (Complete normalization phase): Dietary normalization: Reintroduce normal foods one category at a time (raw vegetables at week 8, fatty foods at week 10, etc.) Discontinue prokinetics: Taper off metoclopramide by week 12 if symptoms allow Monitor for relapse: If symptoms worsen with dietary progression, slow down the reintroduction schedule Adjunctive therapies throughout: Acupuncture: Electroacupuncture at ST36 (Zusanli) has shown benefit in diabetic gastroparesis and may support recovery (Xu et al., Evidence-Based Complementary Medicine , 2014) Abdominal breathing exercises: Diaphragmatic breathing reduces gastric distension and supports motility Avoid medications that worsen motility: Opioids, anticholinergics, calcium channel blockers The protocol assumes functional gastroparesis

The Importance of Monitoring Because tirzepatide is still a new drug, it is important for patients and their doctors to monitor its effects closely, especially if the patient has a history of breast cancer
No study has compared injecting near an injury against injecting elsewhere for these compounds "inject near the injury" is a reasonable, low-cost default, but it is practitioner convention, not an evidence-backed advantage
Whereas Wegovy has the sole intent for use as an anti-obesity drug, weight loss is touted as a side-effect of Ozempic, with the main goal being to treat type 2 diabetes